SEC
NDRM

Seven Eight Capital’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Seven Eight Capital’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-28,700
Closed -$1.12M – 658
2017
Q3 		$1.12M Buy
+28,700
New +$1.06M 0.14% 238

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Seven Eight Capital's NDRM Position: Q4 2017 in Review

Seven Eight Capital sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 28,700 shares — an estimated $1.12M sold.

Seven Eight Capital first reported a position in NDRM in Q3 2017 and held it in 1 quarter. The position peaked at $1.12M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Seven Eight Capital reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Seven Eight Capital sold 28,700 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $1.12M.
  • Seven Eight Capital first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2017 and held it in 1 quarter.
  • Seven Eight Capital's NeuroDerm Ltd. Ordinary Shares position peaked at $1.12M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Seven Eight Capital's 13F filing for Q4 2017, filed 12 Feb 2018.